For the quarter ending 2026-03-31, IMCR made $106,677K in revenue. $5,682K in net income. Net profit margin of 5.33%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| total revenue | 106,677 | 104,478 | 103,693 | 97,964 |
| Cost of revenue from sale of therapies | 434 | 2,703 | 513 | 1,040 |
| Research and development expense | 61,113 | 78,821 | 70,572 | 69,008 |
| Selling, general and administrative expense | 37,850 | 42,645 | 39,779 | 42,791 |
| Income (loss) from operations | 7,280 | -19,691 | -7,171 | -14,875 |
| Interest income | 3,418 | 3,906 | 4,123 | 4,271 |
| Interest expense | 3,051 | 3,053 | 3,043 | 3,045 |
| Foreign currency losss | 3,849 | -1,460 | 1,333 | -738 |
| Other income, net | 1,776 | 4,504 | 5,062 | 4,693 |
| Net income before income taxes | 13,272 | -15,794 | 304 | -9,694 |
| Income tax expense | 301 | 14,266 | 481 | 606 |
| Net income | 12,971 | -30,060 | -177 | -10,300 |
| Exchange differences on translation of foreign operations | -7,289 | 1,922 | -3,392 | 6,476 |
| Total comprehensive income | 5,682 | -28,138 | -3,569 | -3,824 |
| Basic EPS | 0.26 | -0.556 | 0 | -0.2 |
| Diluted EPS | 0.25 | -0.577 | 0 | -0.2 |
| Basic Average Shares | 50,754,763 | 50,598,058 | 50,403,717 | 50,294,205 |
| Diluted Average Shares | 52,934,787 | 48,734,944 | 50,403,717 | 50,294,205 |
Immunocore Holdings plc (IMCR)
Immunocore Holdings plc (IMCR)